Bloomberg’s Poonam Goyal said Walmart’s earnings miss is largely due to lagging pharmaceutical sales impacted by new federal negotiations aimed at delivering lower drug prices. Goyal said that it’s an issue that both the company and investors are expecting to continue affecting sales. Goyal said that Walmart could have the opportunity to calm concerns about flagging US sales growth by focusing on bringing in customers with competitive pricing. (Source: Bloomberg)
Walmart Slides Most Since 2022 on Slowing US Sales Growth
Bloomberg's Poonam Goyal said Walmart's earnings miss is largely due to lagging pharmaceutical sales impacted by new federal negotiations aimed at delivering lower drug prices. Goyal said that it's an issue that both the company and investors are expecting to…
This article was originally published by
Bloomberg Markets
and is republished here under license.
Leave a Reply